Treatment Nonadherence in Inflammatory Bowel Disease: Identification, Scope, and Management Strategies

Inflammatory Bowel Diseases

Volumn 21, Issue 12, 2015, Pages 2979-2984

  Herman, Margot L ^a   Kane, Sunanda V ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

compliance; Crohn's disease; IBD; medication adherence; ulcerative colitis

Indexed keywords

DRUG METABOLITE;

BIOLOGICAL THERAPY; CLASSIFICATION; CLINICAL PRACTICE; COGNITIVE THERAPY; DISEASE ACTIVITY; DISEASE COURSE; HEALTH CARE COST; HUMAN; INFLAMMATORY BOWEL DISEASE; MEDICAL RESEARCH; MEDICATION COMPLIANCE; PHARMACEUTICAL CARE; PHARMACY; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SOCIAL MEDIA; SYSTEMATIC REVIEW (TOPIC); TREATMENT REFUSAL; TREATMENT RESPONSE; DISEASE MANAGEMENT; INFLAMMATORY BOWEL DISEASES;

DISEASE MANAGEMENT; HUMANS; INFLAMMATORY BOWEL DISEASES; MEDICATION ADHERENCE;

EID: 84948180368     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000581     Document Type: Review

References (47)

1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504-1517.
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42; quiz e30.
3. Greenley RN, Kunz JH, Walter J, et al. Practical strategies for enhancing adherence to treatment regimen in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1534-1545.
4. Sabaté E. Adherence to Long Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
5. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11: CD000011.
6. Jackson CA, Clatworthy J, Robinson A, et al. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525-539.
7. Mountifield R, Andrews JM, Mikocka-Walus A, et al. Covert dose reduction is a distinct type of medication non-adherence observed across all care settings in inflammatory bowel disease. J Crohns Colitis. 2014;8: 1723-1729.
8. Elkjaer M, Moser G, Reinisch W, et al. IBD patients need in health quality of care ECCO consensus. J Crohns Colitis. 2008;2:181-188.
9. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26:814-823.
10. Krousel-Wood M, Islam T, Webber LS, et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15:59-66.
11. Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348-354.
12. Trindade AJ, Ehrlich A, Kornbluth A, et al. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis. 2011;17:599-604.
13. Kane S, Becker B, Harmsen WS, et al. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastro-enterol. 2012;107:154-160.
14. Goodhand JR, Kamperidis N, Sirwan B, et al. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1097-1108.
15. Moss AC, Lillis Y, Edwards George JB, et al. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014;109:1850-1855.
16. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047-1053.
17. Gilissen LP, Wong DR, Engels LG, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis. 2012;6:698-707.
18. LeLeiko NS, Lobato D, Hagin S, et al. 6-Thioguanine levels in pediatric IBD patients: adherence is more important than dose. Inflamm Bowel Dis. 2013;19:2652-2658.
19. Hommel KA, Davis CM, Baldassano RN. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:589-593.
20. Mitra D, Hodgkins P, Yen L, et al. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012;12:132.
21. Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29: 247-257.
22. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114: 39-43.
23. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009;26:936-946.
24. Khan N, Abbas AM, Koleva YN, et al. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Inflamm Bowel Dis. 2013;19:1123-1129.
25. Feagins LA, Iqbal R, Spechler SJ. Case-control study of factors that trigger inflammatory bowel disease flares. World J Gastroenterol. 2014; 20:4329-4334.
26. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
27. Ben-Horin S. Loss of response to anti-tumor necrosis factors: what is the next step? Dig Dis. 2014;32:384-388.
28. Fernández-Nebro A, Irigoyen MV, Ureña I, et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol. 2007;34:2334-2342.
29. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020-1024.
30. Kane SV, Sumner M, Solomon D, et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56:3463-3470.
31. Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19:1528-1533.
32. Fidder HH, Singendonk MM, van der Have M, et al. Low rates of adherence for tumor necrosis factor-a inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013;19:4344-4350.
33. Wagnon JH, Leiman DA, Ayers GD, et al. Survey of gastroenterolo-gists' awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: are the guidelines being used and what are the barriers to their use? Inflamm Bowel Dis. 2009;15: 1082-1089.
34. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastro-enterol. 2006;101:1834-1840.
35. Friedman S, Cheifetz AS, Farraye FA, et al. Factors that affect adherence to surveillance colonoscopy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:534-539.
36. Huang V, Mishra R, Thanabalan R, et al. Patient awareness of extraintes-tinal manifestations of inflammatory bowel disease. J Crohns Colitis. 2013;7:e318-24.
37. Friedman S, Cheifetz AS, Farraye FA, et al. High self-efficacy predicts adherence to surveillance colonoscopy in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1602-1610.
38. Hommel KA, Herzer M, Ingerski LM, et al. Individually tailored treatment of medication nonadherence. J Pediatr Gastroenterol Nutr. 2011;53: 435-439.
39. Hommel KA, Hente EA, Odell S, et al. Evaluation of a group-based behavioral intervention to promote adherence in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:64-69.
40. Hommel KA, Hente E, Herzer M, et al. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastro-enterol Hepatol. 2013;25:469-473.
41. Parker S, Chambers White L, Spangler C, et al. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis. 2013;19:1809-1814.
42. Linn AJ, van Dijk L, Smit EG, et al. May you never forget what is worth remembering: the relation between recall of medical information and medication adherence in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:e543-50.
43. Vervloet M, Linn AJ, van Weert JC, et al. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc. 2012;19:696-704.
44. Linn AJ, van Weert JC, Smit EG, et al. 1+1=3? the systematic development of a theoretical and evidence-based tailored multimedia intervention to improve medication adherence. Patient Educ Couns. 2013; 93:381-388.
45. Vodopivec-Jamsek V, de Jongh T, Gurol-Urganci I, et al. Mobile phone messaging for preventive health care. Cochrane Database Syst Rev. 2012; 12:CD007457.
46. Stiles-Shields C, Keefer L. Web-based interventions for ulcerative colitis and Crohn's disease: systematic review and future directions. Clin Exp Gastroenterol. 2015;8:149-157.
47. Banerjee R. P544. Factors associated with drug non-adherence in an Indian IBD patient cohort: it's not always the cost. J Crohns Colitis. 2015;9 (suppl 1):S351-S352.